<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549392</url>
  </required_header>
  <id_info>
    <org_study_id>LRCP02</org_study_id>
    <nct_id>NCT01549392</nct_id>
  </id_info>
  <brief_title>Imaging Study of Glioblastomas Treated With Avastin</brief_title>
  <official_title>Feasibility Study of Magnetic Resonance Spectroscopy and Dynamic Enhanced Cat Scan Imaging in Glioblastomas Treated With and Without Avastin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Regional Cancer Program, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effect of Avastin on brain vascularity and blood-brain
      permeability using dynamic contrast ct scans (DECT) and MRI imaging. Previous publications
      have documented the method by which DECT can determine alterations in vascular volume and
      tissue permeability within tumors and normal brain tissue. Functional maps of cerebral blood
      flow cerebral blood volume and permeability-surface area can be generated from the DECT
      studies to assess tumor perfusion. MRI spectroscopy analyzes brain chemistry to detect tumour
      versus edema versus normal brain. Thirty patients will receive MRI spectroscopy and DECT
      imaging at the time of presumed recurrence and 3 months later. 15 patients who do not receive
      Avastin and 15 patients who do receive Avastin as standard treatment for recurrence will be
      studied with DECT and MRI spectroscopy at baseline and then again in 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical determination of the point of tumour progression or response is difficult to
      determine using standard diagnostic imaging ie CT/MRI especially following previous treatment
      with surgery, radiation and chemotherapy. Hemorrhage, edema, inflammation and vascular
      necrosis.

      Both MR spectroscopy and DECT have been reported as being able to define areas of recurrent
      tumour as opposed to treatment-related effects. We wish to investigate the correlation
      between MR spectroscopy and DECT in assessing tumour progression or response to Avastin in
      comparison with patients not receiving Avastin.

      Health Canada has approved Avastin for clinical use in patients with recurrent glioblastoma
      who have previously received temozolomide and radiotherapy. We propose to perform a DECT scan
      at baseline at presumed tumour progression and again 3 months to determine the effects of
      tumour progression/response on blood brain barrier permeability and vascular volume. The
      group of 15 patients will be compared to a group of 15 patients who do not receive Avastin at
      recurrence involving DECT scanning and MR spectroscopy at the time of the radiological
      progression and 3 months later.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient accrual
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 Month Response</measure>
    <time_frame>at 3 months after initial DECT and MR spectroscopy</time_frame>
    <description>participants who had reduction of tumor size from avastin at 3 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Malignant Gliomas</condition>
  <arm_group>
    <arm_group_label>DECT/MR Spectroscopy +Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DECT/MR Spectroscopy no Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DECT</intervention_name>
    <description>DECT at tumor progression and 3 months later</description>
    <arm_group_label>DECT/MR Spectroscopy +Avastin</arm_group_label>
    <arm_group_label>DECT/MR Spectroscopy no Avastin</arm_group_label>
    <other_name>3 T 64-slice CT scanner (Discovery CT750 HD, GE Healthcare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR spectroscopy</intervention_name>
    <description>MR spectroscopy at tumor progression and 3 months later</description>
    <arm_group_label>DECT/MR Spectroscopy +Avastin</arm_group_label>
    <arm_group_label>DECT/MR Spectroscopy no Avastin</arm_group_label>
    <other_name>MRI scanner: Siemens 3T Tim Trio</other_name>
    <other_name>Sequences: T1W, DTI</other_name>
    <other_name>Analysis software: Brain voyager</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of glioblastoma with clinical or radiological evidence of
             progression as indicated by the RANO criteria 19

          -  Previous radiation and temozolomide chemotherapy

          -  Patients must be receiving Avastin chemotherapy as second-line treatment if in the
             Avastin group

          -  Study-specific consent

        Exclusion Criteria:

          -  Failure to meet inclusion criteria

          -  Pregnant or lactating patients

          -  Allergy to iodine or CT contrast precludes DECT component of study

          -  Claustrophobia precludes MR Spectroscopy component of study

          -  Internal metal which would preclude an MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J Fisher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Regional Cancer Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <results_first_submitted>April 2, 2014</results_first_submitted>
  <results_first_submitted_qc>September 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Barbara Fisher</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>dynamic enhanced ct scan</keyword>
  <keyword>mri spectroscopy</keyword>
  <keyword>recurrent gliomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DECT/MRS in Patients Receiving Avastin</title>
          <description>3 Glioma Patients underwent DECT and MRS pre-Avastin and 3 months later after receiving avastin 10 mg/kg iv q2weeks
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later Avastin 10 mg/kg iv q2weeks</description>
        </group>
        <group group_id="P2">
          <title>DECT/MRS in Glioma Patients Not Receiving Avastin</title>
          <description>0 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patients with recurrent glioblastoma</population>
      <group_list>
        <group group_id="B1">
          <title>DECT/MRS in Patients Receiving Avastin</title>
          <description>-15 Glioma Patients with progression will undergo DECT and MRS pre-Avastin and 3 months later
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
        </group>
        <group group_id="B2">
          <title>DECT/MRS in Glioma Patients Not Receiving Avastin</title>
          <description>15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="45" upper_limit="65"/>
                    <measurement group_id="B3" value="50" lower_limit="45" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>3 Month Response</title>
        <description>participants who had reduction of tumor size from avastin at 3 months</description>
        <time_frame>at 3 months after initial DECT and MR spectroscopy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DECT/MRS in Patients Receiving Avastin</title>
            <description>-15 Glioma Patients with progression will undergo DECT and MRS pre-Avastin and 3 months later
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
          </group>
          <group group_id="O2">
            <title>DECT/MRS in Glioma Patients Not Receiving Avastin</title>
            <description>15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
          </group>
        </group_list>
        <measure>
          <title>3 Month Response</title>
          <description>participants who had reduction of tumor size from avastin at 3 months</description>
          <units>participants who had tumor reduction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DECT/MRS in Patients Receiving Avastin</title>
          <description>-15 Glioma Patients with progression will undergo DECT and MRS pre-Avastin and 3 months later
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
        </group>
        <group group_id="E2">
          <title>DECT/MRS in Glioma Patients Not Receiving Avastin</title>
          <description>15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
DECT: DECT at tumor progression and 3 months later
MR spectroscopy: MR spectroscopy at tumor progression and 3 months later</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Fisher</name_or_title>
      <organization>London Health Sciences Hospital</organization>
      <phone>519-685-8650</phone>
      <email>barbara.fisher@lhsc.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

